Skip Navigation

European Heart Journal 2002 23(4):264-268; doi:10.1053/euhj.2001.2845
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ferguson, J.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferguson, J.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

Moving beyond unfractionated heparin for acute coronary syndromes: Xeno's Paradox revisited

J.J. Ferguson

St Luke's Episcopal Hospital, Texas Heart Institute, Houston, Texas, U.S.A.

References

  1. Antman EM, Cohen M, McCabe C. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1 year follow-up of TIMI 11B and ESSENCE. Eur Heart J. 2002;23:308–314[Abstract/Free Full Text]
  2. Cohen M, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447–452[Abstract/Free Full Text]
  3. Antman EM, McCabe CH, Gurfinkel EP. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601[Abstract/Free Full Text]
  4. Antman EM, Cohen M, Radley DR. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI-11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608[Abstract/Free Full Text]
  5. Antman EM, Cohen M, Bernink PJLM. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. J Am Med Assoc. 2000;284:835–842[Abstract/Free Full Text]
  6. Cohen M, Theroux P, Weber S. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol. 1999;71:273–281[CrossRef][ISI][Medline]
  7. Cohen M, Theroux P, White HD. Anti-thrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation. 2000;102:II-826
  8. Ferguson JJ, Antman EM, Bates ER. The use of enoxaparin and lib/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study. J Am Coll Cardiol. 2001;37:365A
  9. Kereiakes DJ, Grines C, Fry E. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol. 2001;13:272–278[Medline]
  10. Kereiakes DJ, Kleiman NS, Fry E. Dalteparin in combination with abciximab during percutaneous intervention. Am Heart J. 2001;141:348–352[CrossRef][ISI][Medline]
  11. Collet JP, Montalescot G, Lison L. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658–663[Abstract/Free Full Text]
  12. Mark DB, Cowper PA, Berkowitz SD. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation. 1998;97:1702–1707[Abstract/Free Full Text]
  13. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:668–698
  14. Fareed J, Jeskie W, Hoppensteadt D, Clarizo R, Walenga JM. Are the available low-molecular-weight heparin preparations the same? Sem Thromb Hemost. 1996;22:77–91
  15. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol. 2000;35:169–712[Abstract/Free Full Text]
  16. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–1942[CrossRef][ISI][Medline]
  17. Klein W, Buchwald A, Hillis SE. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for six weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997;96:61–68[Abstract/Free Full Text]
  18. Eur Heart J. 1999;20:1553–1562[Abstract/Free Full Text]
  19. Lancet. 1996;347:561–568[CrossRef][ISI][Medline]
  20. Lancet. 1999;354:701–707[CrossRef][ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ferguson, J.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferguson, J.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?